Neuralia TMS Announces TMS therapy Treatment in Melbourne

Australia, 24th May 2024 – Neuralia TMS is pleased to announce the introduction of Transcranial Magnetic Stimulation (TMS) therapy to its suite of mental health treatment options, TMS therapy, a non-invasive brain stimulation technique, has shown significant promise in treating depression and other mental health conditions.

TMS therapy utilises magnetic fields to stimulate specific regions of the brain, primarily targeting areas associated with mood regulation. This advanced treatment is particularly beneficial for patients who have not responded adequately to traditional forms of therapy, such as medication and psychotherapy.

“The introduction of TMS therapy at Neuralia represents a significant advancement in the treatment of depression and other mental health disorders,” said Dr. Shanek Wick, Director of Neuralia TMS. “By offering TMS, the team provides the patients with access to a cutting-edge, evidence-based treatment that has the potential to improve their quality of life significantly.”

The standard TMS treatment protocol involves a series of sessions typically conducted five times a week over a period of four to six weeks. Each session is carried out in a specialised TMS suite equipped with dedicated devices designed to deliver precise magnetic pulses to targeted brain areas. Patient responses to the treatment are carefully monitored and adjusted as needed to ensure optimal outcomes.

Recent studies have highlighted the efficacy of TMS therapy in alleviating symptoms of depression. This therapy has gained attention for its ability to provide relief without the systemic side effects commonly associated with antidepressant medications. Moreover, TMS is being explored for its potential in treating a range of other conditions, including anxiety, PTSD, and chronic pain.

Dr. Wick emphasised the importance of offering a diverse array of treatment options to cater to the unique needs of each patient. “Mental health treatment is not one-size-fits-all. By expanding the services to include TMS therapy, the team is enhancing the ability to tailor treatment plans that best meet the individual needs of patients. This holistic approach is fundamental to the team’s commitment to delivering comprehensive mental health care.”

The introduction of TMS therapy at Neuralia comes at a crucial time when mental health services are in high demand. The impact of the COVID-19 pandemic has underscored the need for effective, accessible mental health treatments. As a result, Neuralia has prioritised the integration of innovative therapies to support the mental well-being of the community.

Looking forward, Neuralia TMS plans to continue expanding its treatment offerings and exploring new avenues for improving mental health care. “The future of mental health treatment lies in continued innovation and research,” Dr. Wick noted. “The team is committed to staying at the forefront of these advancements, ensuring that the patients receive the most effective and up-to-date treatments available.”

The implementation of TMS therapy at Neuralia is expected to benefit a wide range of patients, providing a viable option for those who have struggled with traditional treatments. The therapy’s non-invasive nature and favourable side effect profile make it an attractive alternative for individuals seeking relief from debilitating mental health conditions.

For more information about TMS therapy and other treatment options available at Neuralia, those interested can contact the clinic at (03) 9122 5246 or email at 

Media Contact

Organization: Neuralia TMS (Melbourne)

Contact Person: Dr Shanek Wick



Contact Number: +61391225246

Address: 102/ 149-155 Pascoe Vale Rd

Address 2: Moonee Ponds Vic 3039

Country: Australia

Release Id: 24052412425

The post Neuralia TMS Announces TMS therapy Treatment in Melbourne appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Top Markets News journalist was involved in the writing and production of this article.

Back to top